Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Ascending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55700-0208-48 55700-0208 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 11, 2017 Oct. 11, 2019 In Use
55700-0208-60 55700-0208 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 6, 2016 In Use
55700-0209-15 55700-0209 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 4, 2015 In Use
55700-0209-20 55700-0209 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 16, 2015 Oct. 11, 2019 In Use
55700-0209-21 55700-0209 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 16, 2015 In Use
55700-0209-30 55700-0209 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 16, 2015 In Use
55700-0209-42 55700-0209 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 16, 2015 In Use
55700-0209-48 55700-0209 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 11, 2017 In Use
55700-0458-30 55700-0458 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Nov. 18, 2016 In Use
55700-0458-90 55700-0458 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Nov. 18, 2016 In Use
55700-0484-10 55700-0484 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 13, 2017 In Use
55700-0484-12 55700-0484 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 13, 2017 In Use
55700-0484-20 55700-0484 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 13, 2017 In Use
55700-0484-30 55700-0484 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 13, 2017 In Use
55700-0504-90 55700-0504 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral Feb. 17, 2017 In Use
55700-0508-30 55700-0508 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 3, 2017 June 30, 2019 In Use
55700-0508-90 55700-0508 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 3, 2017 Dec. 31, 2018 In Use
55700-0522-30 55700-0522 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 19, 2017 Dec. 31, 2018 No Longer Used
55700-0627-10 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0627-12 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0627-20 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0627-30 55700-0627 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 18, 2018 In Use
55700-0631-06 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
55700-0631-10 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
55700-0631-20 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
55700-0631-30 55700-0631 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 25, 2018 In Use
55700-0672-10 55700-0672 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 24, 2018 In Use
55700-0672-30 55700-0672 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 14, 2018 Jan. 1, 2019 In Use
55700-0672-65 55700-0672 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 14, 2018 In Use
55700-0728-20 55700-0728 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 17, 2019 Oct. 31, 2019 In Use
55700-0728-21 55700-0728 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 1, 2019 In Use
55700-0733-21 55700-0733 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 15, 2019 In Use
55700-0854-21 55700-0854 Dexamethasone TaperDex 6-day 1.5 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 27, 2020 In Use
55700-0952-65 55700-0952 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 11, 2022 In Use
55700-0961-12 55700-0961 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 31, 2022 In Use
57237-0062-05 57237-0062 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 30, 2007 In Use
57237-0062-30 57237-0062 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 30, 2007 In Use
57237-0062-90 57237-0062 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 30, 2007 In Use
57237-0075-30 57237-0075 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
57237-0075-50 57237-0075 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 4, 2022 In Use
57237-0076-30 57237-0076 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
57237-0076-50 57237-0076 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 4, 2022 In Use
57237-0077-10 57237-0077 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57237-0077-30 57237-0077 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57237-0078-10 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57237-0078-30 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57277-0001-05 57277-0001 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 21, 2017 In Use
57277-0002-10 57277-0002 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 21, 2017 In Use
57277-0105-05 57277-0105 carboplatin Injection Carboplatin 50.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
57277-0106-15 57277-0106 carboplatin Injection Carboplatin 150.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
57277-0107-45 57277-0107 carboplatin Injection Carboplatin 450.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
57377-0025-01 57377-0025 Estradiol pellet Estra-25 25.0 mg/1 Hormonal Therapy Estrogen Subcutaneous Jan. 1, 2017 In Use
57377-0050-01 57377-0050 Estradiol pellet Estra-50 50.0 mg/1 Hormonal Therapy Estrogen Subcutaneous Jan. 1, 2017 In Use
57377-0060-01 57377-0060 Testosterone, USP and Anastrozole Testozole 4.0 mg/1, 60.0 mg/1 Hormonal Therapy Androgen/Aromatase Inhibitor Subcutaneous Jan. 1, 2021 In Use
57582-0101-01 57582-0101 Methylprednisolone Methylprednisolone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 14, 2018 In Use
57582-0101-02 57582-0101 Methylprednisolone Methylprednisolone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 14, 2019 In Use
57664-0020-97 57664-0020 Isotretinoin Isotretinoin 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 2020 In Use
57664-0021-97 57664-0021 Isotretinoin Isotretinoin 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 2020 In Use
57664-0022-97 57664-0022 Isotretinoin Isotretinoin 25.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 2020 In Use
57664-0023-97 57664-0023 Isotretinoin Isotretinoin 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 2020 In Use
57664-0024-97 57664-0024 Isotretinoin Isotretinoin 35.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 2020 In Use
57664-0025-97 57664-0025 Isotretinoin Isotretinoin 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 2020 In Use
57665-0331-01 57665-0331 Cytarabine DepoCyt 50.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal Oct. 22, 2010 June 30, 2018 No Longer Used
57881-0444-01 57881-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0444-10 57881-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0448-01 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0448-10 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57884-2021-01 57884-2021 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 16, 2013 In Use
57884-3021-00 57884-3021 Docetaxel Docetaxel 40.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 15, 2017 Oct. 29, 2021 In Use
57894-0050-60 57894-0050 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 50.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Oral Aug. 11, 2023 In Use
57894-0100-60 57894-0100 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 100.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP17, PARP Oral Aug. 11, 2023 In Use
57894-0111-01 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb. 28, 2022 In Use
57894-0111-02 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb. 28, 2022 In Use
57894-0150-12 57894-0150 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 28, 2011 In Use
57894-0150-25 57894-0150 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Sept. 1, 2015 Aug. 31, 2018 In Use
57894-0155-12 57894-0155 Abiraterone acetate Abiraterone acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Feb. 9, 2018 In Use
57894-0184-12 57894-0184 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 17, 2017 April 18, 2017 No Longer Used
57894-0195-06 57894-0195 Abiraterone Acetate Zytiga 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 17, 2017 In Use
57894-0195-15 57894-0195 Abiraterone Acetate Zytiga 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 17, 2017 In Use
57894-0199-06 57894-0199 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral March 5, 2018 Sept. 2, 2021 In Use
57894-0420-01 57894-0420 Siltuximab Sylvant 100.0 mg/1 Immunotherapy Monoclonal Antibody Interleukin-6 Antagonists Intravenous April 23, 2014 Jan. 31, 2021 No Longer Used
57894-0421-01 57894-0421 Siltuximab Sylvant 400.0 mg/1 Immunotherapy Monoclonal Antibody Interleukin-6 Antagonists Intravenous April 1, 2014 Jan. 31, 2021 No Longer Used
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
57894-0450-01 57894-0450 Teclistamab TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
57894-0469-01 57894-0469 Talquetamab TALVEY 3.0 mg/1.5mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug. 9, 2023 In Use
57894-0470-01 57894-0470 Talquetamab TALVEY 40.0 mg/mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug. 9, 2023 In Use
57894-0501-01 57894-0501 Amivantamab Rybrevant 350.0 mg/1 Immunotherapy Monoclonal Antibody EGFR, MET Intravenous May 21, 2021 In Use
57894-0502-05 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov. 16, 2015 In Use
57894-0502-20 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov. 16, 2015 In Use
57894-0503-01 57894-0503 Daratumumab and hyaluronidase-fihj (human recombinant) Darzalex Faspro 1800.0 mg/15mL, 4.9 mg/15mL, 18.4 mg/15mL, 30000.0 U/15mL, 13.5 mg/15mL, 6.0 mg/15mL, 735.1 mg/15mL Immunotherapy Monoclonal Antibody CD38 Subcutaneous May 1, 2020 In Use
57894-0505-05 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct. 15, 2021 In Use
57894-0505-20 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct. 15, 2021 In Use
57902-0249-05 57902-0249 Asparaginase Erwinaze 10000.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Nov. 18, 2011 July 23, 2021 No Longer Used
57902-0860-03 57902-0860 Samarium SM 153 Lexidronam Quadramet 50.0 mCi/mL Ancillary Therapy Radiopharmaceutical Samarium Sm 153 Intravenous May 19, 1997 In Use
57962-0007-12 57962-0007 Ibrutinib Imbruvica 70.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Aug. 24, 2022 In Use
57962-0014-28 57962-0014 Ibrutinib IMBRUVICA 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec. 20, 2017 In Use
57962-0140-09 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0140-12 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0280-28 57962-0280 Ibrutinib IMBRUVICA 280.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use

Found 10,000 results in 8 millisecondsExport these results